One Biosciences Chooses Albany, NY, as Its U.S. Location

Why It Matters

One Biosciences’ Albany expansion brings advanced single‑cell technology and AI analytics to the U.S., creating high‑skill jobs and attracting $18 million of private investment, which strengthens New York’s position in the competitive life‑science landscape.

Key Takeaways

• One Biosciences will create 42 life‑science jobs in Albany.
• Up to $525,000 in Excelsior Jobs tax credits approved.
• $18 million investment planned over five years for lab and analytics.
• AI‑driven single‑cell profiling will support pharma, biotech, academic partners.

Pulse Analysis

One Biosciences, a Paris‑based startup spun out of Institut Curie, specializes in AI‑enhanced single‑cell profiling that maps the tumor microenvironment with unprecedented resolution. By establishing its first U.S. foothold in Albany, the company taps into a growing regional hub that blends academic research, clinical expertise, and a supportive biotech community. The new facility will house a high‑complexity laboratory equipped for multi‑omics assays alongside a computational analytics center, enabling rapid data processing for pharmaceutical and academic partners seeking to accelerate drug discovery and precision oncology.

The move is bolstered by New York’s Excelsior Jobs Program, which has earmarked up to $525,000 in performance‑based tax credits contingent on hiring 42 specialized life‑science professionals. Over the next five years, One Biosciences plans to invest roughly $18 million in laboratory infrastructure, equipment, and talent development. This infusion of capital not only creates high‑paying jobs but also signals confidence in the state’s incentive framework, encouraging other cutting‑edge biotech firms to consider the Empire State as a strategic growth destination.

From an industry perspective, the Albany site positions One Biosciences at the nexus of AI and single‑cell genomics, fields that are reshaping oncology research worldwide. The proximity to universities such as SUNY Albany and the nearby biotech corridor facilitates collaborations that can translate complex cellular data into actionable therapeutic targets. As pharma companies increasingly rely on high‑throughput, data‑driven insights, One Biosciences’ platform could become a critical partner in early‑stage pipeline validation, reinforcing New York’s reputation as a cradle for next‑generation medical breakthroughs.